Everest Medicines Limited recently announced positive results from an ongoing Phase 1b/2a clinical trial of their next-generation covalent reversible Bruton's tyrosine kinase $(BTK.AU)$ inhibitor, EVER001 (previously known as XNW1011), for the treatment of primary membranous nephropathy (pMN). These results were presented at the 62nd Congress of the European Renal Association (ERA 2025) during a focused oral session. The company continues to advance its innovative mRNA cancer vaccine and in-vivo CAR-T programs, while also focusing on increasing sales and expanding the reach of its other products such as NEFECON® and XERAVA®.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.